Iolyx Therapeutics is a biotechnology research and healthcare service provider for ocular diseases.
Iolyx Therapeutics has raised $15.0M in total funding. The most recent round was Series B. The last funding was announced in December 2025.
Iolyx Therapeutics's investors include Alumni Ventures, Frazier Healthcare Partners, GC&H Investments.
Iolyx Therapeutics is headquartered in Menlo Park, United States.
Iolyx Therapeutics is a biotechnology research and healthcare service provider for ocular diseases.
Iolyx Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Iolyx Therapeutics — Funding & Investors." VCBacked, December 3, 2025, https://www.vcbacked.co/company/iolyx-therapeutics. Accessed September 30, 2026.
VCBacked. (2025). Iolyx Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/iolyx-therapeutics
{{cite web |title=Iolyx Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/iolyx-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated